Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;140(3):809-17.
doi: 10.1053/j.gastro.2010.11.052. Epub 2010 Dec 4.

Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus

Tinsay A Woreta  1 , Catherine G Sutcliffe, Shruti H Mehta, Todd T Brown, Yvonne Higgins, David L Thomas, Michael S Torbenson, Richard D Moore, Mark S Sulkowski
Affiliations

Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus

Tinsay A Woreta et al. Gastroenterology. 2011 Mar.

Abstract

Background & aims: Hepatic steatosis is a common histologic finding in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), although little is known about its natural history. We prospectively examined the natural history of steatosis in patients coinfected with HIV and HCV who attended an urban HIV clinic.

Methods: The study cohort consisted of 222 coinfected patients (87% black, 94% with HCV genotype 1 infection) who had at least 2 liver biopsies performed between 1993 and 2008. Biopsy specimens were scored by a single pathologist; samples were classified as having trivial (<5% of hepatocytes affected) or significant (>5%) levels of fat (steatosis). We characterized progression to significant levels of fat among patients whose first biopsy samples had no or trivial levels of fat, and regression among those with significant fat, using logistic regression.

Results: Initial biopsy specimens from most patients (88%) had no or trivial amounts of fat. Among second biopsy samples, 74% had no or trivial fat and 13% had significant amounts of fat. The strongest risk factors for progression of steatosis were alcohol abuse and overweight/obesity; cumulative exposure to antiretroviral therapy between biopsies and high counts of CD4(+) T cells were associated with reduced progression of steatosis. Among the 28 patients whose initial biopsy specimen had significant fat levels, most (75%) regressed.

Conclusions: Antiretroviral therapy and high counts of CD4(+) T cells are associated with reduced progression of steatosis in patients coinfected with HIV and HCV. Efforts to diagnose and prevent steatosis should focus on persons with a high body mass index and excessive alcohol intake.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None

Figures

Figure 1
Figure 1
Patterns of fat across multiple liver biopsies (N=222).
Figure 2
Figure 2
Steatosis progression at subsequent biopsy by fat score at the initial biopsy of the biopsy pair.
Figure 3
Figure 3
Relationship of the change of and steatosis grade and fibrosis stage (n=222).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197–207. - PubMed
    1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–837. - PubMed
    1. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21:2209–2216. - PubMed
    1. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) AIDS. 2003;17:1803–1809. - PubMed
    1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492–497. - PubMed

Publication types

MeSH terms